Immunological classification of acute myeloblastic leukemias: Relevance to patient outcome

Leukemia

Volumn 17, Issue 3, 2003, Pages 515-527

  Casasnovas, R O ^a   Slimane, F K ^a   Garand, R ^b   Faure, G C ^c   Campos, L ^d   Deneys, V ^e   Bernier, M ^f   Falkenrodt, A ^g   Lecalvez, G ^h   Maynadie M ^a   Bene M C ^c  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^f JULES BORDET INSTITUTE   (Belgium)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h BREST UNIVERSITY HOSPITAL   (France)

Author keywords

AML; Classification; Immunophenotyping; Prognosis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BIOLOGICAL MARKER; CD14 ANTIGEN; CD15 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD36 ANTIGEN; CD7 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; CYTARABINE; DAUNORUBICIN; HLA DR ANTIGEN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MICROSOMAL AMINOPEPTIDASE; RETINOIC ACID; STEM CELL FACTOR RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; CANCER CLASSIFICATION; CANCER RISK; CANCER SURVIVAL; CELL COUNT; CELL DIFFERENTIATION; CHILD; CLUSTER ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMETRY; ERYTHROLEUKEMIA; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; STATISTICAL ANALYSIS; VALIDATION PROCESS;

EID: 0037348958     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402821     Document Type: Article

References (39)

1. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783-1786.
2. Bene MC, Bernier M, Casasnovas RO, Castoldi G, Doekharan D, van der Holt B et al. Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. Br J Haematol 2001; 113: 737-745.
3. Matutes E, Morilla R, Farahat N, Carbonell F, Swansbury J, Dyer M et al. Definition of acute biphenotypic leukemia. Haematologica 1997; 82: 64-66.
4. Garand R, Vannier JP, Bene MC, Faure G, Favre M, Bernard A. Comparison of outcome, clinical, laboratory, and immunological features in 164 children and adults with T-ALL. The Groupe d'Etude Immunologique des Leucemies. Leukemia 1990; 4: 739-744.
5. Garand R, Voisin S, Papin S, Praloran V, Lenormand B, Favre M et al. Characteristics of pro-T ALL subgroups: comparison with late T-ALL. The Groupe d'Etude Immunologique des Leucémies. Leukemia 1993; 7: 161-167.
6. Casasnovas RO, Campos L, Mugneret F, Charrin C, Béné MC, Garand R et al. Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: a prospective study of 432 patients. Leukemia 1998; 12: 34-43.
7. Hartigan JA. Clustering algorithms. New York: Wiley, 1975.
8. Sneath PHA, Sokal RR. Numerical Taxonomy. San Francisco: WH Freeman & Co., 1973.
9. Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza F et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood 1998; 92: 596-599.
10. Buccheri V, Shetty V, Yoshida N, Morilla R, Matutes E, Catovsky D. The role of an anti-myeloperoxidase antibody in the diagnosis and classification of acute leukaemia: a comparison with light and electron microscopy cytochemistry. Br J Haematol 1992; 80: 62-68.
11. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451-458.
12. Huh HY, Pearce SF, Yesner LM, Schindler JL, Silverstein RL. Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood 1996; 87: 2020-2028.
13. van Schravendijk MR, Handunnetti SM, Barnwell JW, Howard RJ. Normal human erythrocytes express CD36, an adhesion molecule of monocytes, platelets, and endothelial cells. Blood 1992; 80: 2105-2114.
14. Lo SK, Golenbock DT, Sass PM, Maskati A, Xu H, Silverstein RL. Engagement of the Lewis X antigen (CD15) results in monocyte activation. Blood 1997; 89: 307-314.
15. Tien HF, Chou CC, Wang CH, Chang CH, Hsing CC. Putative normal counterparts of leukaemic cells from CD7-positive acute myeloid leukaemia can be demonstrated in human haemopoietic tissues. Br J Haematol 1996; 94: 501-506.
16. Chabannon C, Wood P, Torok-Storb B. Expression of CD7 on normal human myeloid progenitors. J Immunol 1992; 149: 2110-2113.
17. Barcena A, Muench MO, Galy AH, Cupp J, Roncarolo MG, Phillips JH et al. Phenotypic and functional analysis of T-cell precursors in the human fetal liver and thymus: CD7 expression in the early stages of T- and myeloid-cell development. Blood 1993; 82: 3401-3414.
18. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
19. Jensen AW, Hokland M, Jorgensen H, Justesen J, Ellegaard J, Hokland P. Solitary expression of CD7 among T-cell antigens in acute myeloid leukemia: identification of a group of patients with similar T-cell receptor beta and delta rearrangements and course of disease suggestive of poor prognosis. Blood 1991; 78: 1292-1300.
20. Venditti A, Del Poeta G, Buccisano F, Tamburini A, Cox-Froncillo MC, Aronica G et al. Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia. Leukemia 1998; 12: 1056-1063.
21. Solary E, Casasnovas RO, Campos L, Bene MC, Faure G, Maingon P et al. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR-phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucemies (GEIL). Leukemia 1992; 6: 393-399.
22. Fergedal M, Astrom M, Tidefelt U, Karlsson MG. Differences in CD14 and alpha-naphthyl acetate esterase positivity and relation to prognosis in AML. Leuk Res 1998; 22: 25-30.
23. Campos L, Guyotat D, Archimbaud E, Devaux Y, Treille D, Larese A et al. Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy. Br J Haematol 1989; 72: 161-166.
24. Bradstock K, Matthews J, Benson E, Page F, Bishop J. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood 1994; 84: 1220-1225.
25. Del Poeta G, Stasi R, Venditti A, Cox C, Aronica G, Masi M et al. CD7 expression in acute myeloid leukemia. Leuk Lymphoma 1995; 17: 111-119.
26. Del Poeta G, Stasi R, Venditti A, Suppo G, Aronica G, Bruno A et al. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 1994; 8: 388-394.
27. Lee EJ, Yang J, Leavitt RD, Testa JR, Civin CI, Forrest A et al. The significance of CD34 and TdT determinations in patients with untreated de novo acute myeloid leukemia. Leukemia 1992; 6: 1203-1209.
28. Geller RB, Zahurak M, Hurwitz CA, Burke PJ, Karp JE, Piantadosi S et al. Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10). Br J Haematol 1990; 76: 340-347.
29. Bassan R, Biondi A, Benvestito S, Tini ML, Abbate M, Viero P, Barbui T et al. Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. Cancer 1992; 69: 396-404.
30. Merle-Beral H, Nguyen Cong Duc L, Leblond V, Boucheix C, Michel A et al. Diagnostic and prognostic significance of myelomonocytic cell surface antigens in acute myeloid leukaemia. Br J Haematol 1989; 73: 323-330.
31. Schwarzinger I, Valent P, Koller U, Marosi C, Schneider B, Haas O Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol 1990; 8: 423-430.
32. Miwa H, Nakase K, Kita K. Biological characteristics of CD7(+) acute leukemia. Leuk Lymphoma 1996; 21: 239-244.
33. Saxena A, Sheridan DP, Card RT, McPeek AM, Mewdell CC, Skinnider LF. Biologic and clinical significance of CD7 expression in acute myeloid leukemia. Am J Hematol 1998; 58: 278-284.
34. Kornblau SM, Thall P, Huh YO, Estey E, Andreeff M. Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance. Leukemia 1995; 9: 1735-1741.
35. Reuss Borst MA, Bühring HJ, Schmidt H, Müller CA. AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. Leukemia 1994; 8: 258-263.
36. Kanda Y, Hamaki T, Yamamoto R, Chizuka A, Suguro M, Matsuyama T et al. The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: an overview of 2483 patients from 22 studies. Cancer 2000; 88: 2529-2533.
37. Kyoda K, Nakamura S, Hattori N, Takeshima M, Nakamura K, Kaya H et al. Lack of prognostic significance of CD34 expression in adult AML when FAB M0 and M3 are excluded. Am J Hematol 1998; 57: 265-266.
38. Lanza F, Rigolin GM, Moretti S, Latorraca A, Castoldi G. Prognostic value of immunophenotypic characteristics of blast cells in acute myeloid leukemia. Leuk Lymphoma 1994; 13(Suppl 1): 81-85.
39. Ciolli S, Leoni F, Caporale R, Pascarella A, Salti F, Rossi-Ferrini P. CD34 expression fails to predict the outcome in adult acute myeloid leukemia. Haematologica 1993; 78: 151-155.